Figure 1个  Table 5个
    • Gene ITGAV ITGB3
      SNPrs3768777 rs3738919 rs5918 rs5921 rs13306487
      Location in gene Intron Intron Exon Exon Exon
      Position 37665539 37730678 4014008 4022879 4023066
      Location in mRNA - - 196 1377 1564
      Nucleotide base A-G A-G C-T A-G A-G
      Amino acid mutation - - Pro-Leu Ile-Val Gln-Arg
      MAF in CHB 0.232 0.058 0.007 0.004 0.050

      Table 1.  Background information of selected SNPs in this study

    • SNP Primers
      rs3768777 rs3768777-p 5′-GTTGCTAATGTTCCGCGTTGCA-3′
      rs3768777-q 5′-GTAGTAGAAGATGGTCCTATCCACG-3′
      rs3768777-a 5′-GGGGGGGGGCTCATCACCCCACCCCCA-3′
      rs3768777-b 5′-GGGGGGGGCGTGCTCCTAACGCTAACAT-3′
      rs3738919 rs3738919-p 5′-ATTTCCAGGTGGAACTTCTTTTGGA-3′
      rs3738919-q 5′-TCACAATTCAGATTTTTGCCACTGG-3′
      rs3738919-a 5′-GGGGGGGGGCGACACAAAGGAAATTTAGA-3′
      rs3738919-b 5′-GGGGGGGGGCGGTGTGACACTTTACAAAG-3′
      rs13306487 rs13306487-p 5′-AAGGCTGAGGAACTCCAGATTG-3′
      rs13306487-q 5′-TGTTTCCAGTGGTTGCAGGTAT-3′
      rs13306487-a 5′-GGGGGGGGGCCGAATGCAGCCCCCA-3′
      rs13306487-b 5′-GGGGGGGGGCACGGGCTGACCCTCCC-3′
      rs5921 rs5921-p 5′-AAGGCTGAGGAACTCCAGATTG-3′
      rs5921-q 5′-TGTTTCCAGTGGTTGCAGGTAT-3′
      rs5921-a 5′-GGGGGGGGGCTCAAGGACAGCCTGATCA-3′
      rs5921-b 5′-GGGGGGGGGCATCAAAGGTGACCTGGAC-3′

      Table 2.  PCR primers used for SNPs amplification

    • SNP Group Genotypes Allele frequency (%)
      aa ab bb χ2 P a b χ2 P
      rs5918 Controls 0 1 100 0.467 0.494 1(0.5) 201(99.5) 0.464 0.496
      Patients 0 2 88 2(1.1) 178(98.9)
      rs3768777 Controls 6 35 60 0.354 0.838 47(23.3) 155(76.7) 0.000 0.988
      Patients 4 34 52 42(23.3) 138(76.7)
      rs3738919 Controls 0 14 87 0.328 0.567 14(6.9) 188(93.1) 0.306 0.580
      Patients 0 10 80 10(5.6) 170(94.4)
      rs13306487 Controls 0 6 95 0.721 0.396 6(3.0) 196(97.0) 0.073 0.402
      Patients 0 3 87 3(1.7) 177(98.3)
      rs5921 Controls 0 0 101 - - - ---
      Patients 0 0 90

      Table 3.  Comparison of genotypes and allele frequencies of candidate SNPs between patients with HFRS and controls

    • Clinical features and laboratory data Mild type (n=9) Medium type (n=49) Severe type (n=11) Gravis type (n=1)
      Age (years)a 25.6±6 34.2±12.9 36.6±18.3 17
      Sex (man/women) 7/2 38/11 7/4 1/0
      WBC count at admission (×109/L)
      < 10 4 14 2
      ≥10 5 35 9 1
      Platelet count at admission (×109/L)
      ≥50 4 12 1
      < 50 5 37 10 1
      Maximum serum creatinine at oliguric phase (μmol/L)a 221.6±83.1 434.6±243.0 698.6±308.6 760.4
      Patient hospital duration (days)a 10.7±2.2 12.0±4.6 15.6±12.3 2.0
      Note: aData are presented as means±SDs

      Table 4.  Demographic, clinical, and hematochemical characteristics in patients with different clinical types of HFRS

    • SNP Clinical type Genotypes Allele frequency (%)
      aa ab bb a b
      rs3768777 Mild 1 1 7 3(8.6) 15(14.3)
      Medium 3 19 27 25(71.5) 73(69.5)
      Severe 0 6 5 6(17.1) 16(15.2)
      Gravis 0 1 0 1(2.8) 1(1.0)
      rs3738919 Mild 0 2 7 2(25.0) 16(12.1)
      Medium 0 4 45 4(50.0) 94(71.2)
      Severe 0 2 9 2(25.0) 20(15.2)
      Gravis 0 0 1 0(0.0) 2(1.5)

      Table 5.  Genotypes and allelic frequencies of rs3768777 and rs3738919 in the integrin αvβ3 gene in patients with different clinical types of HFRS